Company intelligence / Profile preview
Anhui Palo Alto Pharmaceuticals
China
- Ownership
- Private
- Development stage
- Other
01
Overview
PA9159 has advanced to Phase II trials for allergic rhinitis. The drug's mechanism and detailed results have not been published, but its continued progression suggests promising safety/tolerability and preliminary efficacy data.[3] No FDA approvals or late-stage data are available yet.
- Therapeutic areas
- Immunology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships publicly reported as of May 2025.
Beyond the preview
Go deeper on Anhui Palo Alto Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anhui Palo Alto Pharmaceuticals.